NCT04006262View on ClinicalTrials.gov

Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 23, 2019

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Localized Oesogastric AdenocarcimonaMSI and or dMMR
Interventions
DRUG

Nivolumab 10 MG/ML

"Neo-adjuvant treatment : 240 mg intravenous (I.V.) in 30 minutes - every 2 weeks - 6 cycles~\- Adjuvant treatment : 480mg I.V. in 30 minutes - every 4 weeks - 9 cycles"

DRUG

Ipilimumab 200 MG in 40 ML Injection

Neo-adjuvant treatment : 1mg/kg over 30 minutes every 6 cycles - 2 cycles

Trial Locations (15)

35033

CHU Pontchaillou Rennes, Rennes

69373

Centre Léon Bérard, Lyon

Unknown

CHRU Jean Minjoz, Besançon

Hôpital Henri Mondor, Créteil

Institut Hospitalier Franco-Britannique, Levallois-Perret

CHRU Lille, Lille

Hôpital Privé Jean Mermoz, Lyon

ICM Val d'Aurelle, Montpellier

CHU Nantes, Nantes

Hôpital Européen Geroges Pompidou, Paris

Hôpital Saint Antoine, Paris

Hôpital Saint Louis, Paris

Institut Mutualiste Montsouris, Paris

CHU Poitiers, Poitiers

CHU Toulouse, Toulouse

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

GERCOR - Multidisciplinary Oncology Cooperative Group

OTHER

NCT04006262 - Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. | Biotech Hunter | Biotech Hunter